EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nebulized Antibiotics for Preventing and Treating Gram-Negative Respiratory Infections in Critically Ill Patients: An Overview of Reviews

Marios Karvouniaris iD, Despoina Koulenti, Konstantinos I Bougioukas iD, Eirini Pagkalidou, Elizabeth Paramythiotou, Anna-Bettina Haidich iD

Antibiotics · 02.04.2025 · 14 (4) · 370

DOI: 10.3390/antibiotics14040370 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 02.04.2025. Verfasst von Marios Karvouniaris und 5 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, AHEPA University Hospital, 54636 Thessaloniki, Greece. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ventilator-associated tracheobronchitis (VAT) and pneumonia (VAP) are the most frequent nosocomial infections in the critical care setting and are associated with increased morbidity. At the same time, VAP is also associated with attributable mortality, especially when caused by difficult-to-treat (DTR) Gram-negative bacteria (GNB) that have limited treatment options. Studies have assessed the impact of nebulized aminoglycosides or colistin to improve VAT and VAP outcomes or as an adjunct to intravenous antimicrobial treatment or as a preventive approach.

Objective

This overview aimed to assess systematic reviews that examine the efficacy and safety of antimicrobial nebulization for preventing and treating ventilator-associated infections in the critically ill.

Methods

Systematic reviews, meta-analyses, and original randomized controlled trials and prospective observational studies were included. Searches were conducted in MEDLINE (via PubMed), the Cochrane, Epistemonikos, and PROSPERO. The methodological quality assessment was performed using standardized tools.

Results

Regarding VAP treatment, the included systematic reviews presented critically low quality. The clinical response effect size to amikacin and colistin nebulization were RR 1.23 (95% CI 1.13–1.34), I2 = 47% and OR 1.39 (0.87–2.20), I2 = 56%. The main safety concern was bronchospasm with RR 2.55 (1.40–4.66), I2 = 0% and OR 5.19 (1.05–25.52), I2 = 0%. The certainty of evidence was usually very low. For VAT treatment, limited evidence showed a better clinical response and less emergence of resistant bacteria. Regarding VAP prevention, data are limited to two trials; however, only the larger one presented a low risk of bias and resulted in a reduced VAP rate.

Conclusions

Delivery via nebulization might be considered in addition to IV antimicrobial treatment of GNB ventilator-associated infections. The available evidence is weak, and more studies focused on infections due to DTR-GNBs should be prioritized.

Schlagwörter

Stichwörter der Autor:innen

Gram-negative bacteriaamikacinbronchospasmcolistinnebulized antimicrobialsventilator-associated pneumoniaventilator-associated tracheobronchitis

Autor:innen und Institutionen

  • Intensive Care Unit, AHEPA University Hospital, 54636 Thessaloniki, Greece.
  • Department of Critical Care, King's College Hospital NHS Foundation Trust, SE5 9RS London, UK.
  • University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, 4072 Brisbane, Australia.
  • School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, 54110 Ioannina, Greece.
  • Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

ORCID-Profile: Marios Karvouniaris, Konstantinos I Bougioukas, Anna-Bettina Haidich

Zitieren

APA

Karvouniaris, M., Koulenti, D., Bougioukas, K. I., Pagkalidou, E., Paramythiotou, E., & Haidich, A. B. (2025). Nebulized Antibiotics for Preventing and Treating Gram-Negative Respiratory Infections in Critically Ill Patients: An Overview of Reviews. Antibiotics, 14(4), 370. https://doi.org/10.3390/antibiotics14040370

Vancouver

Karvouniaris M, Koulenti D, Bougioukas KI, Pagkalidou E, Paramythiotou E, Haidich AB. Nebulized Antibiotics for Preventing and Treating Gram-Negative Respiratory Infections in Critically Ill Patients: An Overview of Reviews. Antibiotics. 2025;14(4):370. doi:10.3390/antibiotics14040370

BibTeX
@article{Karvouniaris2025,
  author = {Karvouniaris, Marios and Koulenti, Despoina and Bougioukas, Konstantinos I and Pagkalidou, Eirini and Paramythiotou, Elizabeth and Haidich, Anna-Bettina},
  title = {Nebulized Antibiotics for Preventing and Treating Gram-Negative Respiratory Infections in Critically Ill Patients: An Overview of Reviews},
  journal = {Antibiotics},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {370},
  doi = {10.3390/antibiotics14040370}
}
Kostenlos starten →